L. Fu, M. Tian, X. Li, J. Li, J. Huang et al., Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery, Oncotarget, vol.6, pp.5501-5516, 2015.

A. Henssen, T. Thor, A. Odersky, L. Heukamp, N. El-hindy et al., BET bromodomain protein inhibition is a therapeutic option for medulloblastoma, Oncotarget, vol.4, pp.2080-2095, 2013.

S. Muller, P. Filippakopoulos, and S. Knapp, Bromodomains as therapeutic targets, Expert Rev. Mol. Med, vol.13, 2011.

M. A. Dawson, R. K. Prinjha, A. Dittmann, G. Giotopoulos, M. Bantscheff et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia, Nature, vol.478, pp.529-533, 2011.

J. Seal, Y. Lamotte, F. Donche, A. Bouillot, O. Mirguet et al., Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A), Bioorg. Med. Chem. Lett, vol.22, pp.2968-2972, 2012.

A. Wyce, Y. Degenhardt, Y. Bai, B. Le, S. Korenchuk et al., Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer, Oncotarget, vol.4, pp.2419-2429, 2013.

M. Loosveld, R. Castellano, S. Gon, A. Goubard, T. Crouzet et al., Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL, Oncotarget, vol.5, pp.3168-3172, 2014.

H. Qiu, A. L. Jackson, J. E. Kilgore, Y. Zhong, L. L. Chan et al., JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer, Oncotarget, vol.6, pp.6915-6930, 2015.

M. B. Siegel, S. Q. Liu, M. A. Davare, S. E. Spurgeon, M. M. Loriaux et al., Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma, Oncotarget, vol.6, pp.18921-18932, 2015.

A. Heinemann, C. Cullinane, R. De-paoli-iseppi, J. S. Wilmott, D. Gunatilake et al., Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling, Oncotarget, vol.6, pp.21507-21521, 2015.

G. Ambrosini, A. D. Sawle, E. Musi, and G. K. Schwartz, BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells, Oncotarget, vol.6, pp.33397-33409, 2015.

G. Borbely, L. Haldosen, K. Dahlman-wright, and C. Zhao, Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells, Oncotarget, vol.6, pp.33623-33635, 2015.

G. Li, W. Guo, Y. Zhang, J. Seng, H. Zhang et al., Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression, Oncotarget, vol.7, pp.2462-2474, 2016.

T. Hensel, C. Giorgi, O. Schmidt, J. Calzada-wack, F. Neff et al., Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma, Oncotarget, vol.7, pp.1451-1463, 2016.

C. Jacques, F. Lamoureux, M. Baud'huin, L. Rodriguez-calleja, T. Quillard et al., Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1, Oncotarget, vol.7, pp.24125-24140, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01702273

R. C. Montenegro, P. G. Clark, A. Howarth, X. Wan, A. Ceroni et al., BET inhibition as a new strategy for the treatment of gastric cancer, Oncotarget, vol.7, pp.43997-44012, 2016.

C. A. French, Small-Molecule Targeting of BET Proteins in Cancer, Adv. Cancer Res, vol.131, pp.21-58, 2016.

R. Moudgil and E. T. Yeh, Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond, Can. J. Cardiol, vol.32, pp.863-870, 2016.

J. L. Zamorano, P. Lancellotti, D. Rodriguez-muñoz, V. Aboyans, R. Asteggiano et al., ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur. Heart J, vol.37, pp.2768-2801, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01788726

R. Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten et al., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nat. Med, vol.12, pp.908-916, 2006.

E. Falcieri, P. Gobbi, L. Zamai, and M. Vitale, Ultrastructural features of apoptosis, Scanning Microsc, vol.8, pp.653-665, 1994.

J. I. Spiltoir, M. S. Stratton, M. A. Cavasin, K. Demos-davies, B. G. Reid et al., BET acetyl-lysine binding proteins control pathological cardiac hypertrophy, J. Mol. Cell. Cardiol, vol.63, pp.175-179, 2013.

P. Anand, J. D. Brown, C. Y. Lin, J. Qi, R. Zhang et al., BET bromodomains mediate transcriptional pause release in heart failure, Cell, vol.154, pp.569-582, 2013.

Q. Duan, S. Mcmahon, P. Anand, H. Shah, S. Thomas et al., BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure, Sci. Transl. Med, vol.9, 2017.

Y. Sun, J. Huang, and K. Song, BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-?B pathway, Exp Ther. Med, vol.10, pp.2319-2324, 2015.

M. Zengerle, K. Chan, and A. Ciulli, Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4, ACS Chem. Biol, vol.10, pp.1770-1777, 2015.

H. Wang, L. Sharma, J. Lu, P. Finch, S. Fletcher et al., Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion, Oncotarget, vol.6, pp.15857-15870, 2015.

C. V. Dang, Therapeutic targeting of Myc-reprogrammed cancer cell metabolism, Cold Spring Harb. Symp. Quant. Biol, vol.76, pp.369-374, 2011.

F. Li, Y. Wang, K. I. Zeller, J. J. Potter, D. R. Wonsey et al., Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis, Mol. Cell. Biol, vol.25, pp.6225-6234, 2005.

, Int. J. Mol. Sci, vol.20, p.1527, 2019.

J. A. Graves, Y. Wang, S. Sims-lucas, E. Cherok, K. Rothermund et al., Mitochondrial structure, function and dynamics are temporally controlled by c-Myc, PLoS ONE, vol.7, 2012.

J. E. Bolden, N. Tasdemir, L. E. Dow, J. H. Van-es, J. E. Wilkinson et al., Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition, Cell Rep, vol.8, pp.1919-1929, 2014.

R. Ventura-clapier, M. Moulin, J. Piquereau, G. Zurlo, and A. Garnier, Sex differences in anthracycline cardiotoxicity, Ital. J. Gend. -Specif. Med, vol.2, pp.47-54, 2016.

M. Moulin, J. Piquereau, P. Mateo, D. Fortin, C. Rucker-martin et al., Sexual dimorphism of doxorubicin-mediated cardiotoxicity: Potential role of energy metabolism remodeling, Circ. Heart Fail, vol.8, pp.98-108, 2015.

R. Ventura-clapier, M. Moulin, J. Piquereau, C. Lemaire, M. Mericskay et al., Mitochondria: A central target for sex differences in pathologies, Clin. Sci, vol.131, pp.803-822, 2017.

G. W. Richter and K. Solez, Transition Metal Toxicity, p.206, 2013.

A. Krack, R. Sharma, H. R. Figulla, and S. D. Anker, The importance of the gastrointestinal system in the pathogenesis of heart failure, Eur. Heart J, vol.26, pp.2368-2374, 2005.

B. Ranchoux, A. Bigorgne, A. Hautefort, B. Girerd, O. Sitbon et al., Gut-Lung Connection in Pulmonary Arterial Hypertension, Am. J. Respir. Cell Mol. Biol, vol.56, pp.402-405, 2017.

J. L. Dores-sousa, J. A. Duarte, V. Seabra, M. L. De-bastos, F. Carvalho et al., The age factor for mitoxantrone's cardiotoxicity: Multiple doses render the adult mouse heart more susceptible to injury, Toxicology, vol.329, pp.106-119, 2015.

Y. Sun, Y. Wang, T. Toubai, K. Oravecz-wilson, C. Liu et al., BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice, Blood, vol.125, pp.2724-2728, 2015.

M. Jung, K. A. Gelato, A. Fernández-montalván, S. Siegel, and B. Haendler, Targeting BET bromodomains for cancer treatment, Epigenomics, vol.7, pp.487-501, 2015.

A. V. Kuznetsov, V. Veksler, F. N. Gellerich, V. Saks, R. Margreiter et al., Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells, Nat. Protoc, vol.3, pp.965-976, 2008.

D. Wharton and A. Tzagoloff, Cytochrome oxidase from beef heart mitochondria, Methods Enzymol, vol.10, pp.245-250, 1967.